Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202551 · ClinicalTrials.gov registry record · Phase 3
Open-Label Safety Study of ADS-5102 in PD Patients With LID
A Phase 3 study of Parkinsons Disease (PD) and Dyskinesia, sponsored by Adamas Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 223
- Enrollment target
- 20
- Study locations
NCT02202551: Completed Phase 3 study of Parkinsons Disease (PD) and Dyskinesia, sponsored by Adamas Pharmaceuticals.
NCT02202551 is a Phase 3 study of Parkinsons Disease (PD) and Dyskinesia that has completed, run by Adamas Pharmaceuticals. The registered enrollment target is 223 participants, above the 108-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (106% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02202551, a Phase 3 study of Parkinsons Disease (PD) and Dyskinesia, has completed, sponsored by Adamas Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 223 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).
Primary Outcome
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD).
Conditions Studied
Interventions
- DRUG ADS-5102
Study Locations (20)
California
- - Fountain Valley
- - Pasadena
- - Reseda
- - Sacramento
- - Sunnyvale
- - Torrance
- - Ventura
Florida
- - Boca Raton
- - Gainesville
- - Jacksonville
- - Naples
- - Port Charlotte
- - Sunrise
- - Tampa
Arizona
- - Phoenix
- - Scottsdale
- - Sun City
Alabama
- - Birmingham
Colorado
- - Aurora
Connecticut
- - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-02 |
| Phase | Phase 3 |
What the finished NCT02202551 record still lists
NCT02202551 is an interventional study that assigns participants to a tested intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (106% higher).
The record links to 3 conditions, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which ADS-5102 is the first listed.
NCT02202551 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02202551 about?
NCT02202551 is a clinical study titled "Open-Label Safety Study of ADS-5102 in PD Patients With LID". This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).
What is the current status of trial NCT02202551?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 223 participants. The study started on 2014-07. Estimated completion is 2018-02.
What conditions does trial NCT02202551 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD), Dyskinesia, Levodopa Induced Dyskinesia (LID).
What interventions are being tested in trial NCT02202551?
The interventions under investigation include: ADS-5102 (DRUG).
Who is sponsoring clinical trial NCT02202551?
This trial is sponsored by Adamas Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02202551 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02202551's enrollment target sits among peer trials
223 3rd of 19 higher than 17 of 19 other Parkinsons Disease (PD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinsons Disease (PD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
RECRUITING · Phase 3
-
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
COMPLETED · Phase 3
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06640803 · 223 participants · NA
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
- NCT07175285 · 223 participants
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- NCT07205718 · 223 participants · Phase 1
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia